glp-1 drugs overview Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response GLP-1-based therapies for diabetes, obesity

Clinical practice guideline for diabetes management in chronic kidney disease

Natale P, Gutman T, Howell M, et al

Additionally, expanded insurance coverage and favorable regulatory approvals are accelerating market adoption, while ongoing research and development of patient-friendly, long-acting formulations is supporting long-term growth

Although these treatment choices effectively reduce blood glucose levels, they do come with certain drawbacks

The comparison matters because these medications are often presented as equivalent options, and insurance formularies or provider familiarity may steer patients toward one or the other without full consideration of the differences

Retatrutide is a 26-amino acid triple agonist that adds glucagon receptor activation to those two pathways